BioSpecifics Technologies Corp. to Host Conference Call to Report First
Quarter 2013 Financial Results on Friday, May 10, 2013
LYNBROOK, N.Y., May 3, 2013
LYNBROOK, N.Y., May 3, 2013 /PRNewswire/ --BioSpecifics Technologies Corp.
(NASDAQ: BSTC), a biopharmaceutical company developing first in class
collagenase-based products marketed as XIAFLEX^® in the U.S., announced today
that it will host a conference call and live audio webcast at 8:30 a.m. EDT on
Friday, May 10, 2013 to report its first quarter 2013 financial results and
provide a corporate update.
In order to participate in the conference call, please dial 1-800-860-2442
(domestic) or 1-412-858-4600 (international). The live webcast can be accessed
under "Calendar of Events" in the Investor Relations section of the Company's
website at www.biospecifics.com or you may use the link:
A replay of the call will be available one hour after the end of the
conference on May 10, 2013 until 9:00 a.m. EDT on May 27, 2013. To access the
replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088
(international) and reference the access code 10028021. The archived webcast
will be available for 90 days in the Investor Relations section of
BioSpecifics' website at www.biospecifics.com.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has
developed injectable collagenase for twelve clinical indications to date.
Injectable collagenase is marketed as XIAFLEX^® in the U.S. for the treatment
of adult Dupuytren's contracture patients with a palpable cord in the palm by
BioSpecifics' partner, Auxilium Pharmaceuticals, Inc., and is approved for
Dupuytren's contracture in the EU and Canada. XIAFLEX is also in clinical
development for the treatment of several additional promising indications. The
U.S. Food & Drug Administration (FDA) has accepted Auxilium's supplemental
Biologics License Application (sBLA) for filing for XIAFLEX for the potential
treatment of Peyronie's disease. The FDA is expected to take action on the
application by September 6, 2013, and, if approved, XIAFLEX will be the first
and only biologic treatment indicated for Peyronie's disease. Auxilium is also
testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and
cellulite. Auxilium has reported positive top-line data from a Phase IIa
frozen shoulder study and expects to initiate the next phase trial in the
second half of 2013. BioSpecifics is currently managing the clinical
development of XIAFLEX for the treatment of human and canine lipomas, which
are both in Phase II clinical trials, with top-line data from both trials
expected in the second half of 2013. Auxilium is currently partnered with
Asahi Kasei Pharma Corporation for the development and commercialization of
XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan and with
Actelion Pharmaceuticals Ltd. for these same indications in Canada, Australia,
Brazil and Mexico. For more information, please visit www.biospecifics.com.
SOURCE BioSpecifics Technologies Corp.
Contact: BioSpecifics Technologies Corp., Thomas L. Wegman, President, (516)
Press spacebar to pause and continue. Press esc to stop.